Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KISS1R | Q969F8 | 1/20 | 0.41 |
| ▸ | CPB2 | Q96IY4 | 1/20 | 0.35 |
| ▸ | EPHX1 | P07099 | 1/20 | 0.32 |
| ▸ | FOLH1 | Q04609 | 1/20 | 0.31 |
| ▸ | KDM4A | O75164 | 1/20 | 0.31 |
| ▸ | KDM4C | Q9H3R0 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL26231094 | 1.00 | KISS1R (0.41) | KISS1RCPB2EPHX1FOLH1KDM4A | |
| SCHEMBL21297374 | 0.85 | KISS1R (0.39) | KISS1RCPB2EPHX1 | |
| SCHEMBL25132732 | 0.85 | KDM4E (0.35) | — | |
| SCHEMBL16692066 | 0.85 | KISS1R (0.39) | KISS1RCPB2EPHX1 | |
| SCHEMBL24704076 | 0.84 | KISS1R (0.38) | KISS1RCPB2EPHX1FOLH1KDM4A | |
| SCHEMBL25134176 | 0.84 | CYP2C19 (0.39) | — | |
| SCHEMBL22062262 | 0.82 | CA1 (0.44) | — | |
| SCHEMBL20435279 | 0.81 | FOLH1 (0.41) | CPB2FOLH1 | |
| SCHEMBL27250381 | 0.81 | FOLH1 (0.41) | CPB2FOLH1 | |
| SCHEMBL18689009 | 0.81 | FOLH1 (0.41) | CPB2FOLH1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2023057813-A1 | COMPOUNDS, PHARMACEUTICAL COMPOSITIONS, AND METHODS FOR THE TREATMENT, PREVENTION, OR MANAGEMENT OF HYPERPROLIFERATIVE DISORDERS | VINCERX PHARMA GMBH (DE) | 2023-04-13 | — | — | WO | disclosed |
| WO-2022022360-A1 | POLYETHYLENE GLYCOL CONJUGATE DRUG, AND PREPARATION METHOD THERFOR AND USE THEREOF | 重庆阿普格雷生物科技有限公司 | 2022-02-03 | — | — | WO | disclosed |
| WO-2022022354-A1 | POLYETHYLENE GLYCOL CONJUGATE DRUG SYNERGIST, PREPARATION METHOD THEREFOR, AND USE THEREOF | 重庆阿普格雷生物科技有限公司 | 2022-02-03 | — | — | WO | disclosed |
| US-20120264684-A1 | Glycosylated Form of Antigenic GLP-1 Analogue | GLYTECH, INC. (JP) | 2012-10-18 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120264684-A1 | Glycosylated Form of Antigenic GLP-1 Analogue | GLP1R, GIPR, IAPP | KISS1R 305/4885CPB2 1696/4885EPHX1 4605/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.